CrushSCI.com
151.8Average days
130Median days
57Fastest days
331Longest days
1412025 publications

Paper Review Records

All Paper Review Records

23 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

125 days

Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling

Authors
Sjoerd F. Koopman; Erik Sjögren; Peter J. Lenting; Marjon H. Cnossen; Ron A. A. MathôtShow moreShow less
Affiliations
1. Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2. Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden; 3. Pharmetheus, Uppsala, Sweden; 4. Université Paris-Saclay, Institut National de la Santé et de la Recherce Médicale (Inserm), Hémostase Inflammation Thrombose HITh U1176, Le Kremlin-Bicêtre, France; 5. Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The NetherlandsShow moreShow less
Source PDF DOI Publisher page
251 days

Once-Weekly Insulin Icodec: A Review of its Pharmacokinetic and Pharmacodynamic Properties

Authors
T. Heise; M. P. Haridas; N. R. Kristensen; C. Mathieu; R. Ribel-Madsen; T. R. PieberShow moreShow less
Affiliations
1. Profil, Neuss, Germany; 2. Novo Nordisk, Bangalore, India; 3. Novo Nordisk, Søborg, Denmark; 4. Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium; 5. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, AustriaShow moreShow less
Source PDF DOI Publisher page
144 days

The Predictive Value of Gastrin for the Absorption of Erlotinib in Patients with Non-Small Cell Lung Cancer

Authors
Niels Heersche; Daan A. C. Lanser; Sophie M. Ernst; Cornelis Kramers; Marthe S. Paats; Anne-Marie C. Dingemans; Ron H. N. van Schaik; Ron H. J. Mathijssen; G. D. Marijn VeermanShow moreShow less
Affiliations
1. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands; 3. Department of Pulmonology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; 4. Department of Pharmacology-Toxicology and Internal Medicine, Radboud University Medical Center, Nijmegen, The NetherlandsShow moreShow less
Source PDF DOI Publisher page
233 days

Population Pharmacokinetic/Pharmacodynamic Analysis of HHT120, a Novel Direct Thrombin Inhibitor, in Healthy Participants from a Phase I Clinical Trial

Authors
Qingyu Yao; Xue Zhou; Yaou Liu; Jingyi Feng; Ran Xie; Runfeng Lin; Yongxing Wang; Qin Huang; Ying ZhouShow moreShow less
Affiliations
1. Clinical Trial Center, Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Peking University First Hospital, Beijing, China; 2. Livzon Pharmaceutical Group Co., Ltd., Zhuhai, China; 3. Department of Pharmacy, Peking University First Hospital, Beijing, China; 4. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, ChinaShow moreShow less
Source PDF DOI Publisher page
244 days

The Variability in the Pharmacokinetics of Follitropin Alfa: A Systematic Review

Authors
Ranita Kirubakaran; Toni J. F. Michael; Beverley J. Vollenhoven; Vinayak Smith; Sophie L. StockerShow moreShow less
Affiliations
1. Department of Pharmacy, Seberang Jaya Hospital, Penang, Malaysia; 2. School of Clinical medicine, St. Vincent’s Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia; 3. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; 4. Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia; 5. Monash IVF, Melbourne, Australia; 6. Women’s and Newborn Program, Monash Health, Melbourne, Australia; 7. Virtus Health Pty Ltd, Melbourne, Australia; 8. Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, AustraliaShow moreShow less
Source PDF DOI Publisher page
331 days

A Patient-Centered Approach for Drug–Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling

Authors
Cheuk Fung Chan; Young Sun Scaringella; Fenglei HuangShow moreShow less
Affiliations
1. Clinical Pharmacology and Non-Clinical Safety Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does CLINICAL PHARMACOKINETICS take to review a manuscript?

As of 2026-11-18, CrushSCI has 23 complete review records for CLINICAL PHARMACOKINETICS. The fastest paper went from submission to acceptance in 57 days (How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis, received 2026-04-21, accepted 2026-06-17); the slowest took 331 days. The average is 151.8 days and the median is 130 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.